Sulforaphane
Sulforaphane is the broccoli sprout NRF2 activator that increased urinary benzene conjugate excretion 61 percent in 291 Qidong adults (Egner 2014). Negative COPD and pneumonia trials and product form variability hold the BioHarmony score at 5.4 / 10.
Sulforaphane scored 5.4 / 10 (⚖️ Neutral) on the BioHarmony scale as a Substance → Botanical Extract (non-adaptogenic).
What It Is
Sulforaphane is the prototype isothiocyanate from cruciferous vegetables, formed when the inactive precursor glucoraphanin is hydrolyzed by the enzyme myrosinase during chewing, sprouting, gut microbial action, or food preparation. It scored 5.4 / 10 because the Egner 2014 Qidong RCT in 291 adults showed a real pollutant detox signal (urinary benzene conjugate excretion up 61 percent, acrolein up 23 percent) but several broad disease trials in COPD, pneumonia, prediabetes, prostate cancer, and breast cancer have been mixed or negative. Sulforaphane works by adducting cysteine residues on KEAP1, releasing NRF2 to translocate to the nucleus and drive antioxidant response element gene transcription (Itoh 1997, Itoh 1999).
Sulforaphane is the most-studied member of the isothiocyanate family of plant secondary metabolites. The plant stores it as the inactive thioglucoside glucoraphanin in vacuoles, separated from the converting enzyme myrosinase in adjacent cells; tissue damage (chewing, chopping, freezing and thawing, sprouting) brings the two together and forms active sulforaphane. Broccoli sprouts contain 10 to 100 times the glucoraphanin density of mature broccoli (Fahey 1997), which is why sprouts dominate the human-trial literature.
Mechanistically, sulforaphane is best characterized as an indirect antioxidant rather than a direct radical scavenger. It electrophilically adducts reactive cysteine residues on the KEAP1 protein, releasing the transcription factor NRF2 to enter the nucleus, dimerize with small Maf proteins, and drive transcription of phase 2 detoxication enzymes including glutathione S-transferases, NAD(P)H quinone oxidoreductase 1, heme oxygenase 1, and gamma-glutamylcysteine ligase (Itoh 1997, Itoh 1999, Kensler 2007). Secondary mechanisms include histone deacetylase inhibition and modulation of NF-kB signaling. The clinical question is not whether NRF2 activation occurs but whether it translates into hard outcomes in specific human populations.
The clinical case is real but selective. The strongest single signal is pollutant detoxification: Egner 2014 Qidong RCT in 291 adults exposed to high background air pollution showed urinary benzene conjugate excretion up 61 percent and acrolein conjugate excretion up 23 percent on a broccoli sprout beverage. Glycemic effects are real in obese dysregulated subgroups (Axelsson 2017) but did not reach the prespecified threshold in unselected prediabetes (Dwibedi 2025). Autism evidence spans positive (Singh 2014, Ou 2024), missed-primary (Zimmerman 2021), and negative (Hradilova 2023) trials. The big counter-examples are Wise 2016 COPD and De Soyza 2024 pneumonia, where absorbed sulforaphane did not change NRF2 target genes or clinical status. Product form is decisive; Mastaloudis 2026 doubled bioavailability when glucoraphanin was paired with active mustard seed myrosinase.
Terminology
A short glossary clarifies the mechanism, dosing, and trial discussion below. Sulforaphane sits at the intersection of plant biochemistry, redox cell biology, and population epidemiology, and each field uses its own shorthand. Most readers will recognize half of these from other reading; the rest are specific to the isothiocyanate literature, the NRF2 mechanism, or the clinical-trial reporting that determines how to interpret a sulforaphane RCT result.
- Sulforaphane (SFN): The active isothiocyanate molecule. The pharmacologically active species in the body.
- Glucoraphanin: The inactive thioglucoside precursor stored in cruciferous plants. Requires myrosinase to convert to sulforaphane.
- Myrosinase: The plant or microbial enzyme that hydrolyzes glucoraphanin to sulforaphane. Plant myrosinase is destroyed by heat; gut microbial myrosinase substitutes partially.
- NRF2: Nuclear factor erythroid 2-related factor 2. The transcription factor activated by sulforaphane that drives antioxidant response element gene transcription.
- KEAP1: Kelch-like ECH-associated protein 1. The cytosolic brake on NRF2; sulforaphane adducts its cysteines to release NRF2.
- ARE: Antioxidant Response Element. The DNA sequence that NRF2 binds to drive phase 2 enzyme transcription.
- NQO1, HO-1, GST: NAD(P)H quinone oxidoreductase 1, heme oxygenase 1, glutathione S-transferase. Classic NRF2 target enzymes used as biomarkers in trials.
- GSTM1 / GSTT1: Glutathione S-transferase mu 1 and theta 1. Genetic polymorphisms (deletion variants) that change sulforaphane metabolite excretion patterns.
- Brassicaceae: The plant family that includes broccoli, kale, cabbage, brussels sprouts, watercress, mustard, radish, and arugula.
- CYP1A2: A liver cytochrome P450 enzyme that clears caffeine and several drugs. Cruciferous intake can shift its activity.
- CGI / OACIS: Clinical Global Impression and Ohio Autism Clinical Impressions Scale. Standardized outcome scales used in autism trials.
- HbA1c: Glycated hemoglobin. A 3-month average of blood glucose used in the type 2 diabetes and prediabetes trials.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 1 route and 4 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Oral | Broccoli sprouts (raw or lightly steamed), broccoli sprout extract powder, glucoraphanin capsules with active myrosinase, stabilized synthetic sulforaphane | 30 to 200 micromoles per day for 4 to 18 weeks; around 70 grams of broccoli sprouts per day in food-based trials [Egner 2014](https://pubmed.ncbi.nlm.nih.gov/24913818/) Qidong air pollution detox used a broccoli sprout beverage; [Singh 2014](https://pubmed.ncbi.nlm.nih.gov/25313065/) ASD trial used 50 to 150 micromoles per day for 18 weeks; [Axelsson 2017](https://pubmed.ncbi.nlm.nih.gov/28615356/) type 2 diabetes used broccoli sprout extract. | About 8 to 30 milligrams of sulforaphane equivalent per day Community protocols cluster on home-grown broccoli sprouts (about 70 grams per day) or one to two capsules of a glucoraphanin plus myrosinase product taken with food. |
Protocols
Qidong-style detox protocol Clinical
- Dose
- Broccoli sprout beverage delivering about 600 micromoles glucoraphanin or 40 micromoles sulforaphane per day
- Frequency
- Once daily
- Duration
- 12 weeks
Used in the 291-adult Qidong RCT ([Egner 2014](https://pubmed.ncbi.nlm.nih.gov/24913818/)) where urinary benzene conjugate excretion increased 61 percent and acrolein conjugate excretion 23 percent.
Type 2 diabetes glycemic protocol Clinical
- Dose
- Broccoli sprout extract delivering about 150 micromoles sulforaphane per day
- Frequency
- Once daily
- Duration
- 12 weeks
Effects strongest in the obese dysregulated subgroup in [Axelsson 2017](https://pubmed.ncbi.nlm.nih.gov/28615356/); fasting glucose and HbA1c improved.
ASD adolescent and adult protocol Clinical
- Dose
- 50 to 150 micromoles sulforaphane per day, scaled by body weight
- Frequency
- Once daily
- Duration
- 18 weeks
Used by [Singh 2014](https://pubmed.ncbi.nlm.nih.gov/25313065/) where ABC improved about 34 percent and SRS about 17 percent versus placebo, with washout reverting effects.
Home broccoli sprout food protocol Anecdotal
- Dose
- About 70 grams of fresh broccoli sprouts per day
- Frequency
- Once daily, with food
- Duration
- Continuous as a food
Approximates the food intervention used in [Yanaka 2009](https://pubmed.ncbi.nlm.nih.gov/19349290/) for H. pylori activity markers; chew thoroughly to release plant myrosinase.
How this score is calculated →
Upside contribution: 1.67
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 2.6 | 0.650 | |
| Breadth of Benefits | 15% | 3.0 | 0.450 | |
| Evidence Quality | 25% | 2.8 | 0.700 | |
| Speed of Onset | 10% | 3.2 | 0.320 | |
| Durability | 10% | 2.2 | 0.220 | |
| Bioindividuality Upside | 15% | 2.2 | 0.330 | |
| Total | 2.670 |
Upside Rationale
The upside on sulforaphane comes from three places. First, the mechanism is unusually well mapped: KEAP1 cysteine adduction releasing NRF2 to drive phase 2 detoxication and antioxidant gene transcription is a textbook story with foundational papers in the late 1990s (Itoh 1997, Itoh 1999, Kensler 2007). Second, the pollutant detoxification signal in Egner 2014 is real, large, and reproducible at population scale. Third, the glycemic effect in obese dysregulated metabolic patients (Axelsson 2017) is small but trackable, durable, and clinically meaningful. The boundary condition is that broad NRF2 marketing has outrun the clinical evidence; tissue-level NRF2 induction is not universal, and several adequately powered disease trials have been negative.
Efficacy (2.6/5.0): Egner 2014 is the strongest citable finding: 291 adults in Qidong, China, on a broccoli sprout beverage, urinary benzene conjugate excretion increased 61 percent and acrolein conjugate excretion increased 23 percent. Axelsson 2017 reported fasting glucose and HbA1c improvements in 97 type 2 diabetes patients, concentrated in the obese dysregulated subgroup. Singh 2014 ASD trial showed ABC improving about 34 percent and SRS about 17 percent versus placebo in 44 adolescent and adult males. The negatives are large and well-conducted: Wise 2016 COPD found no NRF2 target gene or lung function benefit in 89 patients despite absorption; De Soyza 2024 found no pneumonia benefit in 133 adults; Dwibedi 2025 prediabetes missed its prespecified threshold in 74 adults. The dimension reflects a real but selective effect across populations.
Breadth of Benefits (3.0/5.0): Sulforaphane has documented or plausible activity across several systems but clinically credible breadth is narrower than the mechanism map. The detoxification axis is strongest with the Qidong pollutant data (Egner 2014). The metabolic axis covers fasting glucose, HbA1c, and triglycerides in selected subgroups (Axelsson 2017, Bahadoran 2012). The gut axis covers H. pylori activity markers without eradication (Yanaka 2009). The neuropsychiatric axis covers ASD symptom domains with mixed consistency (Singh 2014, Ou 2024, Hradilova 2023). Cancer prevention remains biomarker level rather than hard outcome (Atwell 2015, Alumkal 2015). Cardiovascular, longevity, and body composition claims are absent at the trial level.
Evidence Quality (2.8/5.0): The evidence base is unusually broad for a phytochemical: multiple RCTs across asthma, autism, type 2 diabetes, prediabetes, H. pylori, prostate cancer, breast cancer, COPD, and pneumonia, plus a 2025 meta-analysis in autism (Wang 2025) and decades of mechanistic and observational work. The dimension is held below 3.5 because of effect heterogeneity, repeated null trials in adequately powered disease studies, and the form-dependence of bioavailability. There is no single Cochrane-grade meta-analysis with a hard clinical endpoint that establishes a clean effect size for any indication. Industry and academic funding are reasonably balanced; the Johns Hopkins lineage and the Talalay legacy provide independent replication for the underlying mechanism work (Prochaska 1992, Zhang 1992, Fahey 1997).
Speed of Onset (3.2/5.0): Bioavailability is fast but clinical effects need weeks. Plasma sulforaphane peaks within 1 to 2 hours of an oral dose and clears within roughly a day (Fahey 2015). Detoxification biomarkers shift within hours to days; the Egner 2014 urinary conjugate excretion changes were detectable within days of starting the broccoli sprout beverage. Clinical endpoints take longer: glycemic effects required 4 to 12 weeks (Axelsson 2017), ASD symptom changes were measured at 18 weeks (Singh 2014), and tissue-level cancer biomarkers required at least biopsy-window dosing (Atwell 2015).
Durability (2.2/5.0): Effects appear use-dependent rather than persistent. ASD symptoms in Singh 2014 faded after washout, and H. pylori activity markers rebounded after stopping in Yanaka 2009. The detoxification effect tracks ongoing exposure rather than a durable shift. NRF2 target gene induction itself is short-lived without continuing dosing because the KEAP1-NRF2 system resets quickly. Daily dosing maintains exposure; intermittent dosing does not produce a clean carryover signal in human trials.
Bioindividuality Upside (2.2/5.0): Response varies meaningfully by GSTM1 and GSTT1 genotype (Gasper 2005, Egner 2014), gut microbiome conversion capacity (Shapiro 1998, Dwibedi 2025), product form (active sulforaphane, glucoraphanin plus active myrosinase, glucoraphanin alone), and disease subgroup. The strong-responder profile is an obese dysregulated metabolic patient on a glucoraphanin product paired with active myrosinase, with intact GSTM1 or GSTT1, and a microbiome capable of conversion. Weak responders include healthy unselected adults on glucoraphanin only products, where exposure is variable and the underlying biology has less to act on. The dimension is held below the median because the predictors of response are partially testable but not yet routine.
Downside contribution: 1.28 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 2.2 | 0.660 | |
| Side Effect Profile | 15% | 2.8 | 0.420 | |
| Financial Cost | 5% | 2.5 | 0.125 | |
| Time/Effort Burden | 5% | 2.0 | 0.100 | |
| Opportunity Cost | 5% | 3.0 | 0.150 | |
| Dependency / Withdrawal | 15% | 1.0 | 0.150 | |
| Reversibility | 25% | 1.5 | 0.375 | |
| Total | 1.980 | |||
| Harm subtotal × 1.4 | 2.247 | |||
| Opportunity subtotal × 1.0 | 0.375 | |||
| Combined downside | 2.622 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 1.282 |
Downside Rationale
The downside on sulforaphane comes from two clusters. First, the supply and form environment introduces real variability: glucoraphanin only products depend on plant or microbial myrosinase that may not be present, and product label claims often diverge from delivered exposure. Second, opportunity cost is real: broad NRF2 marketing claims have outrun the human evidence in COPD, pneumonia, prediabetes, and cancer, so spending dollars or attention on sulforaphane can crowd out interventions with stronger evidence in the same indication. Intrinsic safety is reasonable at studied doses; the practical problems live in formulation, sourcing, and the gap between marketing and trials.
Safety Risk (2.2/5.0): Sulforaphane shows no published catastrophic intrinsic AE signal at studied doses across multiple RCTs in autism, type 2 diabetes, prediabetes, COPD, pneumonia, breast cancer, and prostate cancer. Trial AE rates are mostly mild GI and discontinuation rates are low. Pregnancy and breastfeeding lack specific safety evidence for concentrated extracts and warrant clinician guidance; food-level cruciferous intake is ordinary diet. Hormone-sensitive cancer treatment and active chemotherapy or radiation regimens warrant oncology coordination because of theoretical interactions with cytoprotective biology. Thyroid concerns at studied doses are not supported by Chartoumpekis 2019, where 12 weeks of broccoli sprout beverage did not alter TSH, free T4, thyroglobulin, or thyroid autoimmunity. CYP1A2 modulation at high cruciferous intake can shift caffeine and CYP1A2-cleared drug clearance (Lampe 2000, Hakooz 2007).
Side Effect Profile (2.8/5.0): GI tolerability is the main practical issue. Belching, sulfur odor, loose stools, mild reflux, and indigestion are common in trials, particularly with enteric-coated glucoraphanin plus myrosinase tablets (Fahey 2019). Effects are usually mild but common enough to drive a meaningful subset of users to drop the product. Headache and a perceived detox response are reported anecdotally on day 1. Caffeine sensitivity can shift due to CYP1A2 modulation. Sourcing broccoli sprouts at home introduces a microbiology risk if hygiene is poor; commercial products carry their own quality variability.
Financial Cost (2.5/5.0): Home-grown broccoli sprouts cost cents per dose. Commercial glucoraphanin plus myrosinase products run roughly $25 to $60 per month at clinical doses, and stabilized active sulforaphane products can run higher. The cost-versus-evidence ratio is reasonable for the metabolic-health and pollutant-detox indications but unfavorable for the broader NRF2 marketing claims.
Time/Effort Burden (2.0/5.0): A capsule once or twice per day is trivial. Home sprouting adds 3 to 7 days of growing time per batch with periodic rinsing, which is meaningful for some users and trivial for others. Verifying that a glucoraphanin product contains active myrosinase requires reading certificates of analysis or third-party data.
Opportunity Cost (3.0/5.0): This is the dimension where sulforaphane loses the most ground. Several broad disease indications have stronger evidence-backed alternatives: GLP-1 agonists, metformin, lifestyle programs, or other glucose-lowering tools generally outperform sulforaphane in unselected dysglycemia. Smoking cessation, air filtration, and behavioral pollution-exposure reduction outperform downstream detox biology. NRF2 marketing claims encourage users to spend dollars and attention here that would generate larger returns elsewhere. Sulforaphane stacks logically with cruciferous foods and metabolic programs but does not displace them.
Dependency/Withdrawal (1.0/5.0): No known addictive, withdrawal, or dependency profile. Stopping sulforaphane produces no rebound or withdrawal syndrome.
Reversibility (1.5/5.0): Clean stop. Plasma clearance is essentially complete within a day. NRF2 target gene induction is short-lived without continuing dosing. Effects revert quickly when use ends, with the only persistence being any structural changes to behavior or downstream metabolic improvements that the period of use enabled.
Verdict
The practical verdict on sulforaphane is that it is a reasonable food-level intervention for cruciferous vegetable enthusiasts and a selective supplement for metabolic-health and pollutant-detoxification use cases. It is not the broad-spectrum NRF2 panacea the marketing suggests. The score lands at 5.4 / 10 (Neutral) because the Egner 2014 Qidong detox signal and the Axelsson 2017 glycemic signal are real but several broad disease trials in COPD, pneumonia, prediabetes, prostate cancer, and breast cancer have been mixed or negative. Sulforaphane scores below most well-established metabolic interventions and most NRF2-adjacent tools that have made it to clinical translation. It is meaningfully different from a snake-oil supplement in that the core mechanism is real and reproducible; what holds it back is the gap between what the molecule does in cells and what it has been shown to do in adequately powered human disease trials.
✅ Best for: People with elevated air pollution exposure or dysregulated fasting glucose who can source a glucoraphanin product paired with active myrosinase (Mastaloudis 2026) and will track fasting glucose or hs-CRP for 8 to 12 weeks; obese type 2 diabetes patients in the dysregulated subgroup who have read Axelsson 2017 and accept the small effect size; cruciferous vegetable enthusiasts who want a food-first NRF2 activator and are willing to grow broccoli sprouts at home for cents per dose; users with intact GSTM1 or GSTT1 genotype and a documented gut microbiome conversion capacity who want to test responder status; readers willing to base a supplement trial on objective markers (fasting glucose, HbA1c, hs-CRP, ALT and AST) rather than subjective detox claims.
❌ Avoid if: You are pregnant, breastfeeding, or planning conception with concentrated extracts (food-level cruciferous intake is fine); you are in active chemotherapy, radiation, or hormone-sensitive cancer treatment without oncology approval; you have a history of severe GI sensitivity to brassicas or sulfur compounds; you are on warfarin or other anticoagulants without clinician review; you have severe thyroid disease combined with iodine deficiency and very high raw cruciferous intake; you are buying a glucoraphanin only product without active myrosinase and not relying on gut microbial conversion (exposure will be variable and low); you are looking for a broad-spectrum NRF2 cure-all rather than a selective intervention with subgroup-dependent effects; you are spending opportunity-cost dollars or attention here that would generate larger returns from sleep, training, GLP-1 agonists, smoking cessation, or basic dietary improvements.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Liver / Detoxification: 6.0/10
Score: 6.0/10Detoxification is the strongest single sulforaphane signal in humans. Egner 2014 Qidong RCT in 291 Chinese adults showed urinary benzene conjugate excretion increased 61 percent and acrolein conjugate excretion increased 23 percent on a broccoli sprout beverage delivering glucoraphanin and sulforaphane. The mechanism is direct: NRF2 activates phase 2 detoxication enzymes including glutathione S-transferases and quinone reductase (Itoh 1997, Kensler 2007). Genotype matters; benzene metabolite excretion differed by GSTT1 status (Egner 2014, Gasper 2005). This is a real human detox signal at population scale.
Blood Sugar / Glycemic Control: 5.6/10
Score: 5.6/10Blood sugar is the most practically tracked sulforaphane endpoint. Axelsson 2017 and Dwibedi 2025 together support a fasting glucose effect in dysregulated subgroups, with Dwibedi 2025 showing a responder subgroup reduction around 0.4 millimole per liter despite missing the prespecified 0.3 group threshold. Mechanistically, NRF2 activation supports hepatic gluconeogenesis modulation and oxidative-stress reduction. The score reflects a small-to-moderate, durable, and trackable glycemic signal that is meaningfully diluted in unselected populations and requires 8 to 12 weeks to stabilize.
Antioxidant / Oxidative Stress: 5.5/10
Score: 5.5/10Antioxidant biology is the cleanest single sulforaphane mechanism story. NRF2 target gene activation drives glutathione synthesis, glutathione S-transferases, NQO1, and HO-1, supporting endogenous antioxidant capacity rather than direct radical scavenging. Itoh 1997 and Itoh 1999 established the NRF2 and KEAP1 mechanism, and Kensler 2007 reviews ARE-driven cytoprotection. The Qidong RCT (Egner 2014) demonstrated phase 2 detox biomarker shifts at population scale. Tissue-level NRF2 target induction is not universal; Wise 2016 absorbed sulforaphane did not change NQO1, HO1, or AKR1C1 in COPD lung tissue.
Metabolic Health: 5.4/10
Score: 5.4/10Metabolic health is one of the better-supported sulforaphane indications. Axelsson 2017 reported broccoli sprout extract improved fasting glucose and HbA1c in 97 type 2 diabetes patients, with effects concentrated in the obese dysregulated subgroup. Bahadoran 2012 showed triglyceride and oxidized-LDL-to-LDL ratio improvements in 81 type 2 diabetes adults over 4 weeks. The negative is Dwibedi 2025, where prediabetes adults missed the prespecified 0.3 millimole per liter fasting glucose threshold, with overall reduction of 0.2 millimole per liter and a responder subgroup at 0.4. Effects are real but subgroup-dependent and modest.
Anti-Inflammatory: 5.0/10
Score: 5.0/10Anti-inflammatory effect is biologically real but clinical translation is mixed. Selected cytokine and gastritis marker shifts are documented in small trials, and NRF2 activation suppresses NF-kB signaling preclinically. The negatives are notable: Wise 2016 COPD showed no inflammation movement in 89 patients, and several disease-specific inflammatory trials have failed primary endpoints. The dimension reflects mechanistic strength against repeated trial inconsistency. Nouchi 2022 older adult cohort showed no significant TNF-alpha movement despite functional outcome changes, suggesting some clinical effects route through pathways other than measured systemic inflammation markers.
Gut Health / Microbiome: 5.0/10
Score: 5.0/10Gut evidence is mixed and dominated by H. pylori work. Yanaka 2009 reported that 70 grams of broccoli sprouts per day reduced urease breath and stool antigen markers during treatment in 48 to 50 humans, with rebound after stopping. Chang 2015 confirmed lower lipid peroxidation in gastric mucosa but did not eradicate infection. Microbiome-mediated conversion of glucoraphanin is itself a source of bioindividuality (Shapiro 1998). GI tolerability is the most common practical issue, with belching and loose stools reported in trials, particularly with enteric-coated formulations.
| Use Case | Score | Summary |
|---|---|---|
| ⚖️ Cardiovascular | 4.8 | Cardiovascular evidence is observational and indirect rather than RCT-anchored. Higher cruciferous vegetable intake is associated with lower stroke and cardiovascular mortality in cohort work (Joshipura 1999, Zhang 2011), and air pollution detox biology supports a plausible cardiovascular mechanism (Egner 2014 showed 61 percent and 23 percent increases in benzene and acrolein conjugate excretion). Lipid effects in the type 2 diabetes Bahadoran 2012 trial are supportive but small. Direct sulforaphane RCTs with cardiovascular endpoints are absent, and the cohort signal cannot isolate sulforaphane from whole-food diet patterns or other Brassica constituents. |
| ○ Immune Function | 4.5 | Mechanism work shows nasal immune and cytokine modulation, but the broader immune-disease trial signal is weak. NRF2 activation and KEAP1-NRF2-ARE biology are well mapped (Kensler 2007), and small studies suggest pollutant-driven immune effects can be modulated. The strongest negatives are De Soyza 2024, where stabilized synthetic sulforaphane at 300 milligrams per day did not improve community-acquired pneumonia clinical status or NRF2 target modulation in 133 adults, and Wise 2016 where 89 COPD patients showed no benefit. Score reflects mechanistic plausibility and selected human signals against repeated disease-trial failures. |
| ○ Respiratory | 3.0 | Respiratory results are mixed. Nasal immune and pollutant detox signals exist, but Wise 2016 found no COPD NRF2 target gene, inflammation, antioxidant, or lung function benefit in 89 patients despite confirmed absorption. De Soyza 2024 found no community-acquired pneumonia benefit. Cohort-level Brassica intake associations are not respiratory-specific. |
Frequently Asked Questions
What is the best form of sulforaphane to buy?
The most predictable products either contain active sulforaphane or pair glucoraphanin with active myrosinase, which doubled bioavailability from about 18.6 to 39.8 percent in Mastaloudis 2026. Glucoraphanin only products depend on plant or gut microbial myrosinase to convert to active sulforaphane, and that conversion varies meaningfully by gut microbiome (Shapiro 1998). Home grown broccoli sprouts at about 70 grams per day deliver food level glucoraphanin and active myrosinase together if chewed thoroughly. Choose by exposure, not by sulforaphane label claim alone.
Does sulforaphane actually activate NRF2 in humans?
Sometimes, in some tissues, with major exceptions. The Qidong air pollution RCT (Egner 2014) showed urinary benzene conjugate excretion increased 61 percent and acrolein conjugate excretion 23 percent in 291 adults, which is downstream NRF2 phase 2 activity. The big counterexample is Wise 2016 where absorbed sulforaphane did not change NQO1, HO1, AKR1C1, or AKR1C3 in 89 COPD patients. NRF2 activation is real but tissue, dose, and disease state dependent.
Can sulforaphane help blood sugar or prediabetes?
It can help selected metabolic subgroups, with effects that are real but modest. Axelsson 2017 reported improved fasting glucose and HbA1c in 97 type 2 diabetes patients, with effects strongest in the obese dysregulated subgroup. Dwibedi 2025 prediabetes RCT in 74 adults missed its prespecified 0.3 millimole per liter fasting glucose threshold, with overall reduction of 0.2 and a responder subgroup around 0.4. Bahadoran 2012 showed triglyceride and oxidized LDL improvements in 81 type 2 diabetes patients.
Is sulforaphane useful for autism symptoms?
Promising but inconsistent. Singh 2014 was positive in 44 adolescent and adult males, with ABC improving about 34 percent and SRS about 17 percent versus placebo. Zimmerman 2021 missed the primary OACIS outcome in 45 children. Hradilova 2023 was negative on behavioral outcomes. Ou 2024 reported significant improvements in 108 children but needs careful replication. Wang 2025 meta-analysis is cautiously positive but heterogeneous.
Does sulforaphane prevent cancer?
Human cancer evidence is biomarker level, not hard prevention proof. Atwell 2015 raised sulforaphane metabolites in 54 women with breast biopsy windows, but most tissue biomarker changes were not significant after correction. Cipolla 2015 reported PSA doubling time improvement in about 78 prostate biochemical recurrence patients on stabilized sulforaphane. Alumkal 2015 extended PSA doubling time from 6.1 to 9.6 months in 20 patients but did not meet a 50 percent PSA decline endpoint.
What are the side effects and interactions of sulforaphane?
Most reports are mild GI: belching, sulfur odor, loose stools, and reflux, with enteric coated glucoraphanin plus myrosinase tablets causing more abdominal discomfort than uncoated forms (Fahey 2019). CYP1A2 modulation can shift caffeine clearance (Lampe 2000, Hakooz 2007). Chartoumpekis 2019 found 12 weeks of broccoli sprout beverage did not alter TSH or thyroid autoimmunity. Pregnancy and active oncology regimens warrant clinician guidance.
How should someone monitor whether sulforaphane is working?
Anchor an 8 to 12 week trial on objective markers, not subjective detox. Track fasting glucose and HbA1c as the most replicable signal in dysglycemia (Axelsson 2017, Dwibedi 2025). Add hs-CRP for inflammatory tone, triglycerides for the lipid signal, and ALT and AST as safety guardrails. Pulse score Body for GI tolerability and Drive for processing speed changes. If fasting glucose has not moved by week 12 in a dysregulated person, the responder probability is low.
How fast should I see effects from sulforaphane?
Bioavailability and detox biomarkers shift within hours to days, while clinical outcomes need weeks. The Qidong RCT showed urinary benzene and acrolein conjugate excretion changes within days of starting the broccoli sprout beverage (Egner 2014). Glycemic and ASD endpoints required 12 to 18 weeks at trial doses. Plasma sulforaphane peaks within 1 to 2 hours and clears within roughly a day, so daily dosing maintains exposure. Run an 8 to 12 week trial before judging fasting glucose or hs-CRP response.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
The most plausible score-moving event is a Cochrane-grade meta-analysis with a hard clinical endpoint in dysglycemia or pollutant detoxification, which would lift Evidence from 2.8 to 3.5 or 4.0 and add roughly 0.5 to 1.0 points. A second positive Phase III replication of the Singh 2014 ASD signal would lift Efficacy and Evidence together. A clean Phase III win in a broad disease indication (heart failure, NASH, neurodegeneration) would substantially reframe the case. The downside risks are also asymmetric: a major safety signal in pregnancy or oncology populations would push Safety up (worse) and Reversibility into reversibility-with-consequences territory, and a meta-analysis showing the glycemic signal is artifact of small obese subgroups would strip Efficacy down toward 2.0.
| Scenario | Dimension shifts | New Score |
|---|---|---|
| Cochrane meta-analysis with hard endpoint in dysglycemia | Evidence 2.8 to 3.8, Efficacy 2.6 to 3.2 | 6.1 / 10 👍 Worth Trying |
| Phase III replication of Singh 2014 ASD effect | Evidence 2.8 to 3.4, Efficacy 2.6 to 3.0 | 5.9 / 10 👍 Worth Trying |
| Clean Phase III win in heart failure, NASH, or neurodegeneration | Evidence 2.8 to 3.8, Breadth 3.0 to 3.8, Efficacy 2.6 to 3.4 | 6.4 / 10 👍 Worth Trying |
| New active-myrosinase product class becomes routine and cheap | Bioindividuality 2.2 to 3.2, Cost 2.5 to 1.8 | 5.7 / 10 ⚖️ Neutral |
| Major pregnancy or oncology safety signal | Safety 2.2 to 3.5, Reversibility 1.5 to 2.5 | 4.7 / 10 ⚠️ Caution |
| Meta-analysis shows glycemic signal is small-subgroup artifact | Efficacy 2.6 to 1.8, Evidence 2.8 to 2.2 | 4.7 / 10 ⚠️ Caution |
Key Evidence Sources
- Egner PA et al. Rapid and sustainable detoxication of airborne pollutants by broccoli sprout beverage in Qidong, China. Cancer Prev Res. 2014.. Flagship pollutant detox RCT. n=291. Benzene conjugate excretion +61 percent, acrolein +23 percent.
- Singh K et al. Sulforaphane treatment of autism spectrum disorder. PNAS. 2014.. Double-blind RCT in 44 males with ASD. ABC improved about 34 percent, SRS about 17 percent vs placebo.
- Axelsson AS et al. Sulforaphane reduces hepatic glucose production. Sci Transl Med. 2017.. Mechanistic plus type 2 diabetes RCT. n=97. Fasting glucose and HbA1c improved in obese dysregulated subgroup.
- Dwibedi C et al. Effect of broccoli sprout extract on glucose metabolism in prediabetes. Nat Microbiol. 2025.. Prediabetes RCT, n=74. Missed prespecified 0.3 mmol/L threshold; responder subgroup about 0.4.
- Yanaka A et al. Dietary sulforaphane-rich broccoli sprouts reduce H. pylori colonization. Cancer Prev Res. 2009.. Human and mouse H. pylori. About 48 to 50 humans on 70 g per day broccoli sprouts. Markers down during use, no eradication.
- Wise RA et al. Lack of effect of oral sulforaphane on NRF2 target gene expression in COPD. PLOS One. 2016.. n=89 COPD. No NQO1, HO1, AKR1C1, AKR1C3, inflammation, antioxidant, or lung function benefit despite absorption.
- De Soyza A et al. Stabilized synthetic sulforaphane in community-acquired pneumonia. ERJ Open Res. 2024.. n=133 pneumonia RCT. 300 mg per day did not improve WHO clinical status or NRF2 target modulation.
- Itoh K et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through ARE. Biochem Biophys Res Commun. 1997.. Foundational NRF2 and small Maf control of phase 2 genes through antioxidant response elements.
- Itoh K et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 1999.. Foundational KEAP1 and NRF2 mechanism.
- Kensler TW et al. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol. 2007.. Canonical KEAP1-NRF2-ARE cytoprotective signaling review.
- Bahadoran Z et al. Effect of broccoli sprouts on insulin resistance in type 2 diabetes. Eur J Clin Nutr. 2012.. n=81 RCT. Triglycerides and oxidized LDL to LDL ratio improved over 4 weeks.
- Mastaloudis A et al. Mustard seed myrosinase doubles sulforaphane bioavailability from glucoraphanin extract. J Nutr. 2026.. Crossover bioavailability study, n=16. 39.8 percent vs 18.6 percent with myrosinase.
- Shapiro TA et al. Human metabolism and excretion of cancer chemoprotective glucosinolates and isothiocyanates of cruciferous vegetables. Cancer Epidemiol Biomarkers Prev. 1998.. Showed myrosinase and gut flora govern conversion of glucosinolates to isothiocyanate metabolites.
- Atwell LL et al. Sulforaphane bioavailability and chemopreventive activity in women receiving prophylactic mastectomy. Cancer Prev Res. 2015.. n=54 breast biopsy RCT. Metabolites raised; most tissue biomarker changes not significant after correction.
- Alumkal JJ et al. A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer. Invest New Drugs. 2015.. n=20. PSA doubling time 6.1 to 9.6 months. Did not meet 50 percent PSA decline endpoint.
- Nouchi R et al. Effects of sulforaphane on processing speed and mood in healthy older adults. Int J Mol Sci. 2022.. n=144 older adults. Improved processing speed and negative mood over 12 weeks. HO-1, GST, TNF-alpha, BDNF unchanged.
- Wang Y et al. Sulforaphane in autism spectrum disorder: systematic review and meta-analysis. Eur Child Adolesc Psychiatry. 2025.. Systematic review and meta-analysis through 2024. Cautiously positive but heterogeneous.
- Chartoumpekis DV et al. Broccoli sprout beverage is safe for thyroid hormonal and autoimmune status. Food Chem Toxicol. 2019.. 12 weeks broccoli sprout beverage did not alter TSH, free T4, thyroglobulin, or thyroid autoimmunity.
- Zhang Y et al 1992 - A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure.. Auto-resolved via strict PubMed lookup (author+year+topic match)
Holistic Evidence Profile
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Medium
Citations: Egner 2014, Singh 2014, Axelsson 2017, Dwibedi 2025, Wise 2016, De Soyza 2024, Mastaloudis 2026
Pre-RCT-Era Pharmacology and Use
Confidence: Limited
Citations: Prochaska 1992, Zhang 1992, Fahey 1997, Itoh 1997, Kensler 2007, Verhoeven 1996, Joshipura 1999
Traditional Medicine Systems
Confidence: Limited
Citations: Gao 2022, Dang 2023, Manohar 2009, European Agency 1998, Woodman 2003
Holistic Evidence for Sulforaphane
Modern and traditional lenses agree on cruciferous foods as broadly useful, but only the modern lens addresses standardized sulforaphane extracts. The historical lens shows discovery is recent, which explains why traditional protocols target whole plants and pungent preparations rather than isolated isothiocyanates.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- Fasting Glucose Baseline (pre-protocol) During | Expected Down
- HbA1c Baseline (pre-protocol) During | Expected Down
- Triglycerides During | Expected Down
- hs-CRP Baseline (pre-protocol) During | Expected Down
- ALT During | Expected Stable
- AST During | Expected Stable
- TSH Baseline (pre-protocol) During | Expected Stable
Pulse Dimensions to Watch
- Energy During | Expected Watch | Secondary
- Body During | Expected Watch | Primary
- Drive During | Expected Up | Tertiary
- Calm During | Expected Watch | Tertiary
Subjective Signals (Daily Voice Card)
- GI Comfort Scale 1-5 | During | Expected Watch
- Belching Or Sulfur Odor Scale 1-5 | During | Expected Watch
- Perceived Detox Or Headache Scale 1-5 | During | Expected Watch
- Focus And Processing Speed Scale 1-5 | During | Expected Up
- Caffeine Sensitivity Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Persistent diarrhea or abdominal pain
- New reflux, nausea, or inability to tolerate the product
- Jaundice, dark urine, or ALT or AST above 3x baseline
- New palpitations, insomnia, or major caffeine response change
- Active chemotherapy, radiation, or hormone-sensitive cancer treatment without oncologist approval
- Pregnancy or breastfeeding with concentrated extract use unless clinician-guided
- Thyroid disease with very high raw cruciferous intake or iodine deficiency
Other interventions for Anti-Inflammatory
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–3.6, Caution 3.7–4.7, Neutral 4.8–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–7.9, Top-tier 8.0+.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 1.670 − 1.282 = 0.388
Formula v0.5 maps EV = 0 to score 5.0. Above neutral, 1 EV point equals 1 score point. Below neutral, 1 EV point equals about 0.71 score points, so EV = −7 reaches 0.0 while EV = +5 reaches 10.0. Both sides use the full 5-point half-scale.
Score = 5 + (0.388 / 5) × 5 = 5.4 / 10
